 |
|
Use of Meperidine in Patient-Controlled Analgesia and the Development of a Normeperidine Toxic Reaction
Thomas T. Simopoulos, MD;
Howard S. Smith, MD;
Christine Peeters-Asdourian, MD;
Donald S. Stevens, MD
Arch Surg. 2002;137:84-88.
Hypothesis Intravenous patient-controlled analgesia (IV PCA) meperidine hydrochloride can be used with a reasonable margin of safety.
Design A retrospective review was performed of 355 medical records of patients receiving IV PCA meperidine treatment. Four groups of patients were defined, based on daily meperidine dose and the presence or absence of central nervous system excitation adverse effects. Use of more than 600 mg/d of meperidine hydrochloride was considered a high dose.
Setting University tertiary care hospital.
Participants Postoperative patients from general, orthopedic, neurosurgical, gynecological, and urologic procedures receiving IV PCA.
Interventions If patients were judged to have consumed significant amounts of meperidine, the analgesic regimen was modified to (1) discontinue meperidine therapy, (2) substitute hydromorphone hydrochloride, or (3) decrease the use of meperidine by adding oral methadone hydrochloride or transdermal fentanyl citrate to the regimen.
Main Outcome Measures Patients who received less than 10 mg/kg per day of IV PCA meperidine hydrochloride therapy were unlikely to experience central nervous system excitatory adverse effects and maintain adequate analgesia.
Results The mean meperidine hydrochloride consumption for those patients classified as high dose, asymptomatic was 13.3 mg/kg per day (95% confidence interval, 12.1-14.4 mg/kg per day). This differed statistically significantly (P<.05) from the mean meperidine hydrochloride dose in patients classified as high dose, symptomatic, which was 16.9 mg/kg per day (95% confidence interval, 14.7-19.2 mg/kg per day). The duration of meperidine use did not differ among the 4 patient groups. The incidence of a central nervous system toxic reaction associated with IV PCA meperidine therapy was 2%.
Conclusions We recommend 10 mg/kg per day as a maximum safe meperidine hydrochloride dose by an IV PCA device for no longer than 3 days. Daily patient evaluation is mandatory. Care must also be taken when using this dose to ensure the absence of renal dysfunction or enhanced hepatic metabolism of meperidine.
From the Department of Anesthesiology and Critical Care, Postoperative Pain Services (Dr Simpoulos), Cancer Pain and Palliative Care (Dr Smith), and the Arnold Pain Management Center (Dr Peeters-Asdourian), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Mass; and the Department of Anesthesiology, University of Massachusetts Medical Center, Worcester (Dr Stevens).
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
CYP2B6, CYP3A4, AND CYP2C19 ARE RESPONSIBLE FOR THE IN VITRO N-DEMETHYLATION OF MEPERIDINE IN HUMAN LIVER MICROSOMES
Ramirez et al.
Drug Metab. Dispos. 2004;32:930-936.
ABSTRACT
| FULL TEXT
Acute Pain Management
Koo
Journal of Pharmacy Practice 2003;16:231-248.
ABSTRACT
|
